Characteristics of patients randomized to the golimumab treatment arm at the FDA-approved dosage in included studies.
| Study | Intervention Group Drugs | Comparator | Women, % | Age, Yrs, Mean (SD) or Median (IQR) | Prior MTX Failure | Prior Biologic Failure | MTX Dose, mg/wk, Mean (SD) or Median (IQR) | HAQ, Baseline, Mean (SD) or Median (IQR) | Disease Duration, Yrs, Mean (SD) or Median (IQR) | DAS28, Baseline, Mean (SD) or Median (IQR) | No. DMARD Failed, Mean (SD) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Smolen 199938 | Golimumab + MTX | PL + MTX | 74 | 55 (46, 63) | Yes, 67% | Yes, TNF inhibitor | —†† | 1.6 (1.1, 2.0) | 9.6 (5.6, 17.2) | 6.3 (5.6, 7.2) | —†† |
| Kay 200937 | Golimumab + MTX | PL + MTX | 86 | 57 (50, 64) | Yes | No | —†† | 1.7 (1.4, 2.0) | 8.2 (4.1, 14.3) | 5.3 (4.5, 6.2)* | —†† |
| Keystone 200936 | Golimumab + MTX | PL + MTX | 81 | 51 (42, 59) | Yes | No | 15.0 (15.0, 20.0) | 1.4 (1.0, 1.9) | 4.5 (2.1, 9.7) | 5.1 (4.1, 5.6)* | —†† |
| Emery 200939 | Golimumab + MTX | PL + MTX | 85 | 51 (11) | No† | No | 12.8 (2.2) | 1.5 (0.7) | 3.5 (5.7) | 5.1 (1.0)* | —†† |
↵* Disease Activity Score 28-joint count using C-reactive protein level.
↵† Half of patients were exposed to other DMARD, including but not limited to hydroxychloroquine, sulfasalazine, leflunomide, etc.
↵†† Data not provided. FDA: US Food and Drug Administration; IQR: interquartile range; MTX: methotrexate; HAQ: Health Assessment Questionnaire; DMARD: disease-modifying antirheumatic drug; TNF: tumor necrosis factor.